arrow
R

Richard M. Stone

Dana-Farber Cancer Institute
H指数:132
被引数:7.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Infectious complications of treatment for acute lymphoblastic leukemia in adults: Is antifungal prophylaxis necessary? A single-center retrospective cohort study

成人急性淋巴细胞白血病的治疗相关感染并发症:是否需要抗真菌预防?一项单中心回顾性队列研究

2026-10-100
OA
Epigenetic markers expand genetic risk estimation in acute myeloid leukemia

表观遗传标记扩展急性髓系白血病的遗传风险评估

Blood
IF23.1
2026-09-110
OA
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia

BRAF突变在急性髓系白血病中的预后和治疗意义

Leukemia
IF13.4
2026-06-150
OAAI
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML

Venetoclax/FluBu2 缓和性化疗移植后,采用全口服 venetoclax/decitabine 维持治疗高危 MDS/AML

2025-12-090
OAAI
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study

通讯内容:口服地西他滨+西达佐瑞ribine,联合或未联合维奈克拉,治疗高风险骨髓增生异常综合征或慢性骨髓单核细胞白血病的倾向性评分匹配研究

2025-11-040
OAAI
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse

自造血干细胞移植(HCT)后复发急性髓系白血病(AML)并达到缓解的患者,细胞疗法巩固治疗并无明确益处。

2025-11-040
OAAI
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

跨大陆成人急性髓系白血病的多维分析揭示了突变景观和治疗结局中的年龄相关趋势(Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

Leukemia
IF13.4
2025-09-190
OAAI
Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein

通过靶向细胞表面RNA结合蛋白对急性髓系白血病模型的治疗

2025-04-230
OA
Myelodysplastic Syndromes, Version 2.2025 Featured Updates to the NCCN Guidelines

骨髓增生异常综合征,版本2.2025 NCCN指南特色更新

2025-03-010
PRE
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study
CANCER
IF5.1
2025-02-061
OAAI
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

Asciminib 联合达沙替尼和泼尼松治疗费城染色体阳性急性白血病

BLOOD
IF23.1
2025-02-062
PRE
The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia- an International Multicenter Cohort Study

RUNX1突变在初诊急性髓系白血病中的预后和预测价值——一项国际多中心队列研究

BLOOD
IF23.1
2024-11-050
PRE
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Bleximenib剂量优化及携带KMT2A和NPM1基因变异的复发/难治性急性白血病患者1期研究的RP2D确定

BLOOD
IF23.1
2024-11-055
PRE
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

10年随访研究:CALGB 10603/Ratify试验中,年龄18-60岁新诊断FLT3突变急性髓系白血病患者的米哚妥林与安慰剂联合强化化疗的比较

BLOOD
IF23.1
2024-11-050
PRE
Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

成人急性髓系白血病(AML)患者中Y染色体单独缺失及其对适应性免疫的影响研究

BLOOD
IF23.1
2024-11-050
PRE